Glutamine antagonists and uses thereof

US12195419B2 · kind B2 · utility

Assignees

• The John Hopkins University · US
• USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. · CZ

Inventors

• Barbara Slusher · Kingsville, US
• Rana Rais · Kingsville, US
• Pavel Majer · Sykesville, US
• Lukas Tenora · Praha, CZ
• Katerina Novotna
• Jesse Alt · Essex, US

Key dates

• Filing date: Oct 5, 2018
• Grant date: Jan 14, 2025
• Expiry date: Jun 1, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2603/74
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Glutamine antagonists and their use for treating oncological, immunological, and neurological diseases are disclosed. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder, the method comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof. Also disclosed are methods of enhancing the effects of an immune checkpoint inhibitor, enabling a subject to respond to an immune checkpoint inhibitor, or enabling the toxicity or the dose or number of treatments with an immune checkpoint inhibitor to be reduced, comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof, and an immune checkpoint inhibitor. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder that is refractory to checkpoint inhibitor therapy, the method comprising administering to a subject in need thereof, and having the refractory disease or d…